Connect with us

Cannabis

MustGrow Commences Banana ‘Panama Disease’ Testing in Colombia

Newsfile

Published

on

  • National State of Emergency declared in Colombia in 2019.
  • Panama Disease is existential threat to the $25 billion global banana industry.
  • Disease remains viable in soil for decades – no effective treatments currently available.
  • MustGrow’s natural bio-pesticide technology has shown 100% control of similar diseases.

Saskatoon, Saskatchewan–(Newsfile Corp. – September 29, 2020) – MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0) (the “Company“, “MustGrow“) announces the commencement of testing of MustGrow’s proprietary TerraMG bio-pesticide formulation on the Panama Disease (Fusarium wilt TR4), a devastating disease pathogen ravaging the $25 billion global banana industry. MustGrow’s TerraMG bio-pesticide has been proven to control soil-borne diseases similar to Panama Disease.

The laboratory testing in Colombia will focus on the treatment of the Panama Disease. MustGrow’s previous independent efficacy studies in Canada have proven that TerraMG’s treatment of Fusarium oxysporum, a soil-borne pathogen, had 100% control of the fungus. Panama Disease is among the most destructive banana diseases, affecting particularly Cavendish bananas, which are half of all bananas produced globally. Currently, there are no effective treatments for the infected banana plantations, with the disease remaining viable for decades in the soil and can cause 100% yield loss.

MustGrow has already been working towards its US-EPA and Canadian-PMRA registrations of TerraMG for pre-plant treatment of soil-borne pests and diseases in high value crops such as fruits & vegetables. Now, MustGrow is replicating this strategy in Colombia’s besieged banana industry – focused on controlling and eliminating the Panama Disease. This work will build on MustGrow’s existing field data and serve as a benchmark for achieving registration labels in Colombia and other leading South American agricultural countries. MustGrow anticipates laboratory results in Q4-2020.

“This is an exciting program for MustGrow, as we push the boundaries of our bio-pesticide into a new continent with a currently untreatable disease,” remarked MustGrow CEO Corey Giasson. “With both banana producers and banana consumers rooting for us, we look forward to potentially providing a much needed solution for Colombian farmers.”

The spread of Panama Disease through banana plantations in South America has prompted Colombia to reportedly declare a National State of Emergency, enacting special measures to stop the disease from spreading, including the preventive eradication of 168 hectares of infected crop. A flurry of media reports has followed, revealing a race to save bananas from extinction after the disease has left a trail of scorched banana plantations in its wake.

About MustGrow

MustGrow is a publicly traded (CSE: MGRO) (OTCQB: MGROF) (FRA:0C0) agriculture biotech company focused on providing natural science-based biological solutions for high value crops, including fruits & vegetables. MustGrow has designed and owns a United States EPA-approved natural solution that uses the mustard seed’s natural defence mechanism to protect plants from pests and diseases. Over 110 independent tests have been completed, validating MustGrow’s safe and effective signature products. The product, in granule format, is EPA-approved across all key U.S. states and by Health Canada’s PMRA (Pest Management Regulatory Agency) as a bio-pesticide for high value crops such as in fruit & vegetables. MustGrow has now concentrated a liquid format which it’s calling TerraMG, and with regulatory approval, could be applied through standard drip or spray equipment, improving functionality and performance features.

The Company has approximately 37 million basic common shares issued and outstanding. For further details please visit www.mustgrow.ca.

ON BEHALF OF THE BOARD

“Corey Giasson”
Director & CEO
Phone: +1-306-668-2652
info@mustgrow.ca

Forward-Looking Statements

Certain statements included in this press release constitute “forward-looking statements” which involve known and unknown risks, uncertainties and other factors that may affect the results, performance or achievements of MustGrow.

Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects”, “is expected”, “budget”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might”, “occur” or “be achieved.”

Forward-looking statements are subject to a number of risks and uncertainties that may cause the actual results of MustGrow to differ materially from those discussed in such forward-looking statements, and even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on, MustGrow.

These risks are described in more detail in MustGrow’s Prospectus and other continuous disclosure documents filed by MustGrow with the applicable securities regulatory authorities and available at www.sedar.com. Readers are referred to such documents for more detailed information about MustGrow, which is subject to the qualifications, assumptions and notes set forth therein.

This release does not constitute an offer for sale of, nor a solicitation for offers to buy, any securities in the United States.

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

© 2020 MustGrow Biologics Corp. All rights reserved.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/64739

Cannabis

PURA 1-for-1 Shareholder Dividend of PAOG Shares on Track

Newsfile

Published

on

Dallas, Texas–(Newsfile Corp. – October 30, 2020) – PAO Group, Inc. (OTC Pink: PAOG) and Puration, Inc. (OTC: Pink: PURA) today released an update on the process underway for PAOG to issue PAOG shares to PURA shareholders in a dividend distribution.

PAOG acquired a cannabis cultivation operation from PURA earlier this year in a transaction that includes issuing PAOG shares to PURA shareholders. The target distribution ratio calls for PURA shareholders receiving one share of PAOG for every one share of PURA owned.

PAOG has executed two acquisitions in recent months and managed to ramp up and organize acquired cannabis pharmaceutical research assets as necessary to execute a contract prerequisite to developing its acquired cannabis pharmaceutical research assets into an FDA approved drug. PAOG admits the dividend distribution process has lagged behind the acquisition and pharmaceutical development contract efforts. Last week, after completing the pharmaceutical development contract, PAOG management and PURA management committed to rapidly completing the dividend issuance.

Since initiating the joint rapid dividend completion effort, PAOG has filed to redomicile the company to Wyoming and increase the authorized number of shares in order to have the necessary inventory to execute the dividend distribution. PAOG has also engaged the services of the company’s transfer agent to manage the dividend distribution of PAOG stock to PURA shareholders. Once the move to Wyoming is complete, PAOG will file with the necessary financial regulatory authority to finalize the dividend details. PAOG anticipates a definitive dividend distribution announcement will be forthcoming within the next two weeks.

PAOG is excited to make PURA shareholders also PAOG shareholders.

The developing PAOG and PURA partnership includes PAOG participating in PURA’s new hemp lifestyle brand strategy, called Farmersville Brands and headquartered on a 72-acre property currently under contract for acquisition by PURA. In conjunction with PAOG’s newly acquired cultivation business, PAOG plans to build a pharmaceutical grade, indoor hemp cultivation operation and lab on PURA’s Farmersville property.

Look for more information coming soon from both PURA and PAOG.

For more information on PAO Group, visit www.paogroupinc.com.

For more information on Puration, visit www.purationinc.com.

Disclaimer/Safe Harbor:

This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company’s current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies’ contracts, the companies’ liquidity position, the companies’ ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.

Contact:
Puration, Inc.
Brian Shibley,
info@aciconglomerated.com
(800) 861-1350

PAO Group, Inc.
Jim DiPrima
888-272-6472
info@pao.group

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/67197

Continue Reading

Cannabis

Early Warning Report in Connection with the Sale of 5,500,000 Subordinate Voting Shares of Green Thumb Industries Inc.

Newsfile

Published

on

Chicago, Illinois–(Newsfile Corp. – October 30, 2020) – On October 29, 2020, RCP23, LLC (the “Seller”), a private investment holding company controlled by Benjamin Kovler, CEO and Chairman of Green Thumb Industries Inc. (CSE: GTII) (OTCQX: GTBIF) (the “Issuer”), sold 5,500,000 Subordinate Voting Shares of the Issuer (the “Transferred Shares”) to a third-party qualified institutional buyer at a purchase price of C$19.25 per share in a private transaction. Prior to the sale, at Seller’s request, the Issuer converted 54,805 Super Voting Shares and 49,448 Multiple Voting Shares of the Issuer previously held by the Seller into an aggregate 10,425,300 Subordinate Voting Shares per the terms of the Issuer’s Articles of Incorporation, as amended.

Following the sale, Mr. Kovler, together with his joint actors, holds beneficial ownership or control or direction over 183,254 Super Voting Shares, which represent 56.5% of the class, 0 Multiple Voting Shares, and 5,068,016 Subordinate Voting Shares, which represent less than 2.9% of the class. Each Super Voting Share carries 1,000 votes and is convertible into one Multiple Voting Share and each Multiple Voting Share carries 100 votes and is convertible into 100 Subordinate Voting Shares (each of which carries one vote).

For further information, please contact Investor Relations, Green Thumb Industries Inc., InvestorRelations@GTIgrows.com, Phone: 310-622-8257.

This press release is issued pursuant to National Instrument 62-103 – The Early Warning System and Related Take-Over Bid and Insider Reporting Issues, which requires an early warning report to be filed on SEDAR (www.sedar.com) containing additional information with respect to the foregoing matters. A copy of this report may be obtained by contacting Investor Relations, Green Thumb Industries Inc., InvestorRelations@GTIgrows.com, Phone: 310-622-8257.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/67179

Continue Reading

Cannabis

Special Guests and Lovers of Psychedelics Are “Coming Out of the Chemical Closet” to Celebrate New Book about MDMA — Register For Virtual Book Launch

Newsfile

Published

on

New York, New York–(Newsfile Corp. – October 30, 2020) –  Charley Wininger and his publisher Inner Traditions are welcoming the arrival of his book “Listening to Ecstasy: The Transformative Power of MDMA” with a free virtual night of storytelling on Nov 13th, 7:00 PM (Eastern Time). Members of the press are invited to join this unique event. To register click link HERE.

Cannot view this image? Visit: https://i1.wp.com/grassnews.net/wp-content/uploads/2020/10/special-guests-and-lovers-of-psychedelics-are-coming-out-of-the-chemical-closet-to-celebrate-new-book-about-mdma-register-for-virtual-book-launch.jpg?w=740&ssl=1

To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/6896/67182_770a79eed47178a9_001full.jpg

Charley will be joined by several psychedelic luminaries, and hosted by comedian Sarah Rose Siskind. They will share intimate, touching and humorous stories about a time their lives were transformed by the often misunderstood underground party drug, MDMA.

In his book, “Listening to Ecstasy” Charley reveals how MDMA has enhanced his marriage both erotically and emotionally, and describes how pleasure, fun, and joy can be profound bonding and transformative experiences.

Cannot view this image? Visit: https://i1.wp.com/grassnews.net/wp-content/uploads/2020/10/special-guests-and-lovers-of-psychedelics-are-coming-out-of-the-chemical-closet-to-celebrate-new-book-about-mdma-register-for-virtual-book-launch-1.jpg?w=740&ssl=1

To view an enhanced version of this graphic, please visit:
https://grassnews.net/wp-content/uploads/2020/10/special-guests-and-lovers-of-psychedelics-are-coming-out-of-the-chemical-closet-to-celebrate-new-book-about-mdma-register-for-virtual-book-launch-1.jpg

“This is also the story of how my wife and I entered a forbidden world of drug users, and found it to be enchanted. MDMA opened up our lives to new friends, fun, and freedom. It’s also helped us navigate the aging process as we transitioned from middle age into our sixties and seventies.” – Charley Wininger

Wininger’s writing and personal narrative shows how MDMA can be a tool for healing and connection. This is why this particular psychedelic compound is being studied to treat Post-Traumatic Stress Disorder (PTSD) with Phase 3, peer-reviewed trials taking place at research sites in the U.S., Canada, and Israel. (Multidisciplinary Association for Psychedelic Studies, 2020). At the current pace, MDMA will be a prescription medication in the U.S. by 2023.

In a recent Forbes article, Charley referred to MDMA as “super glue for relationships“. He and his wife are open to giving candid interviews about how MDMA helps to strengthen their connection.“It can help you connect with yourself, with your loved ones and with the world at large, [which] is especially important now when we live in a time of isolation and fear.” – Charley Wininger (Forbes)

Members of the media

  1. Check out the Charley Wininger Media Kit for quotes and downloadable images
  2. Book interview with Charley before launch (Nov. 13th)
  3. Request media review copy of Listening to Ecstasy

Please reach out to:
Alana Armstrong
Alana@alanaldous.com
Alex Krause
Alex@alanaldous.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/67182

Continue Reading

Trending Online

Grassnews is part of PICANTE Media and Events, a leading media and boutique event organizer in the European Union with a monthly reach of +50,000 readers. The official company (PROSHIRT SRL), has been listed for 4 years in a row among the top 3 Advertising and market research agencies in the local Top Business Romania Microcompanies based on the Financial Reports. Grassnews digests / hand picks the latest news about the CBD / Legal Cannabis industry and serves them to you daily.

Contact us: sales@picante.today

Editorial / PR Submissions

© Grassnews .com 2019 - 2020 - part of PICANTE Media. All rights reserved. Registered in Romania under Proshirt SRL, Company number: 2134306, EU VAT ID: RO21343605. Office address: Blvd. 1 Decembrie 1918 nr.5, Targu Mures, Romania